Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Novartis
UBS
Fish and Richardson
McKinsey
Baxter
Mallinckrodt
US Department of Justice
Citi
US Army
Deloitte

Generated: January 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,295,641

« Back to Dashboard

Which drugs does patent 9,295,641 protect, and when does it expire?

Patent 9,295,641 protects ALPHAGAN P and is included in two NDAs.

Protection for ALPHAGAN P has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-seven patent family members in nineteen countries.
Summary for Patent: 9,295,641
Title:Compositions containing alpha-2-adrenergic agonist components
Abstract: Compositions useful for improving effectiveness of alpha-2-adrenergic agonist components include carrier components, alpha-2-adrenergic agonist components, solubility enhancing components which aid in solubilizing the alpha-2-adrenergic agonist components. In one embodiment, the alpha-2-adrenergic agonist components include alpha-2-adrenergic agonists. In another embodiment, the solubility enhancing components include carboxymethylcellulose.
Inventor(s): Graham; Richard (Irvine, CA), Bakhit; Peter (Huntington Beach, CA), Olejnik; Orest (Coto De Caza, CA)
Assignee: ALLERGAN, INC. (Irvine, CA)
Application Number:14/484,017
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 9,295,641

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Allergan ALPHAGAN P brimonidine tartrate SOLUTION/DROPS;OPHTHALMIC 021770-001 Aug 19, 2005 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Allergan ALPHAGAN P brimonidine tartrate SOLUTION/DROPS;OPHTHALMIC 021262-001 Mar 16, 2001 AT RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 9,295,641

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,627,210 Compositions containing .alpha.-2-adrenergic agonist components ➤ Subscribe
9,687,443 Compositions containing alpha-2-adrenergic agonist components ➤ Subscribe
6,641,834 Compositions containing alpha-2-adrenergic agonist components ➤ Subscribe
6,673,337 Compositions containing alpha-2-adrenergic agonist components ➤ Subscribe
8,858,961 Compositions containing alpha-2-adrenergic agonist components ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 9,295,641

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Japan 4927298 ➤ Subscribe
Japan 2008231122 ➤ Subscribe
Japan 2008511628 ➤ Subscribe
Taiwan I287998 ➤ Subscribe
Russian Federation 2311928 ➤ Subscribe
New Zealand 521185 ➤ Subscribe
New Zealand 599669 ➤ Subscribe
Poland 360707 ➤ Subscribe
Norway 333367 ➤ Subscribe
Norway 20024221 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Novartis
Johnson and Johnson
Chubb
Covington
Cipla
US Department of Justice
Fuji
Baxter
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot